CuraYou's ProWave Deep Healing Pad™ delivers red and infrared light therapy for rheumatoid arthritis in a device you can use at home every day. It takes the kind of light treatment that has been studied in laboratories and clinics for over two decades and builds it into a flexible, medical-grade pad that wraps around affected joints and treats the whole area in one session. The clinical and mechanistic research behind red light therapy for rheumatoid arthritis now spans three meta-analyses, multiple randomized controlled trials, and an extensive body of molecular evidence identifying nine distinct biological mechanisms. But research only helps the person sitting at home with swollen, stiff joints if it is built into something they can actually use. This article covers exactly how the Cura ProWave Deep Healing Pad™ does that: which wavelengths it uses, why it uses LEDs instead of lasers, how much power it delivers, and what treatment routine CuraYou recommends for RA.
Part of our complete guide to Red and Infrared Light Therapy for Rheumatoid Arthritis.
Key Takeaways
- The wavelengths match the RA research. The Cura ProWave Deep Healing Pad™ delivers 850 nm near-infrared light from 240 light chips and 660 nm red light from 120 light chips (360 in total) at 200 mW/cm² across an 18 × 8 inch flexible pad. Both wavelengths sit within the 610–850 nm range used across the RA evidence base: the Ryu et al. (2023) head-to-head comparison with methotrexate used 610 nm, the Harvard/Massachusetts General Hospital study (Yamaura et al., 2009) used 810 nm, and the Adly et al. (2022) human randomized trial used 808 nm.
- LED delivers the same biological response as laser at matched wavelength and dose. Heiskanen and Hamblin (2018) of Massachusetts General Hospital and Harvard concluded that photobiomodulation does not depend on lasers or coherence, and that LED therapy appears as effective as laser therapy for surface-tissue applications. The cellular mechanism is wavelength-dependent, not device-dependent.
- The protocol aligns with what worked in trials. CuraYou recommends daily 20-minute sessions using the pre-set modes. The RA clinical trials that showed significant results used treatment courses of daily or near-daily sessions over four to ten weeks. Three modes (red only, infrared only, or combined) let you target surface inflammation, deeper joint tissue, or both.
- Results build within the 60-day return window. The Adly et al. (2022) trial measured significant improvements in inflammatory markers, oxidative stress, ATP levels, and quality of life at four weeks. The Cochrane review analyzed studies with treatment durations of four to ten weeks. CuraYou's 60-day risk-free return guarantee covers the timeline the research shows is needed to evaluate response.
What the Research Requires
How Red and Infrared Light Therapy Help Rheumatoid Arthritis
Red and infrared light therapy (photobiomodulation) works on multiple biological systems that drive RA simultaneously. When specific wavelengths of light penetrate tissue and reach the mitochondria of cells, they trigger a chain of responses that suppress the inflammatory cascades fueling joint destruction, reduce the cytokines that biologic drugs costing thousands of dollars per month are designed to block, reprogram immune cells from a tissue-destroying state to a repair state, protect cartilage from enzymatic degradation, reduce the oxidative stress that amplifies inflammation, and restore the cellular energy production that chronic inflammation depletes. A 2023 study published in Frontiers in Immunology (Ryu et al.) compared photobiomodulation directly to methotrexate, the first-line RA drug, using the gold-standard collagen-induced arthritis model. Photobiomodulation suppressed the same NF-κB and NLRP3 inflammatory pathways as methotrexate, and the combination of both was significantly more effective than either treatment alone. A Harvard/Massachusetts General Hospital study (Yamaura et al., 2009) demonstrated that near-infrared light reduced TNF-α and IL-1β (the same cytokines targeted by the most expensive biologic RA medications) in synoviocytes taken from actual RA patients.
Three meta-analyses have evaluated the clinical outcomes. The most recent and largest, Salajegheh et al. (2024), pooled 22 randomized controlled trials and found significant improvements in grip strength and significant reductions in morning stiffness. The Brosseau et al. (2000) meta-analysis found a 70% pain reduction relative to placebo and a 27.5-minute reduction in morning stiffness. The Cochrane review (2005) concluded that laser therapy should be considered for short-term relief of pain and morning stiffness in RA, particularly since it has few side effects. The full mechanism and clinical evidence is covered in our complete guide to red light therapy for rheumatoid arthritis.
Wavelength, Dose, and Protocol
For any device to deliver these benefits, the research points to specific requirements. Wavelengths in the 610–850 nm range are where the RA evidence is concentrated. The Ryu et al. (2023) study used 610 nm at 10 mW/cm² for 40 minutes daily and achieved significant suppression of NF-κB and NLRP3 inflammatory pathways. The Yamaura et al. (2009) Harvard study found cytokine suppression at 810 nm and 5–25 J/cm². The Adly et al. (2022) human randomized trial used 808 nm and measured significant reductions in C-reactive protein, IL-6, and oxidative stress markers. The Hsieh et al. (2014) dosimetry study established that low-to-moderate fluence (4.5 J/cm²) was effective while high fluence (72 J/cm²) was not, confirming that photobiomodulation follows a biphasic dose response where both too little and too much reduce the effect, as Hamblin (2017) documented in his comprehensive review.
The trials with the strongest results used treatment courses of daily or near-daily sessions over several weeks. The Adly et al. (2022) trial measured significant outcomes at four weeks. The Cochrane review analyzed studies with treatment durations of four to ten weeks. Direct analgesic mechanisms such as selective nerve fiber inhibition and endogenous opioid activation can produce pain relief from the first sessions, while the deeper anti-inflammatory and cellular energy effects accumulate over a course of regular treatment. Clinically meaningful improvements in grip strength, morning stiffness, and quality of life build over weeks of consistent use.
The therapy has a strong safety record across all three RA meta-analyses and the individual trials. No serious adverse events have been reported. The 2025 umbrella review by Son et al. found no evidence of harm across 204 randomized controlled trials spanning multiple conditions. The treatment is non-invasive, does not cause immunosuppression, does not interact with RA medications, and has been studied specifically as an adjunct to methotrexate with no adverse interactions. What matters for results is delivering the right wavelengths at sufficient power density with consistent daily use, parameters that vary widely across consumer devices.
RA medications target specific points in the inflammatory cascade, and they do it well. But the disease operates across multiple biological systems simultaneously, i.e. inflammation, immune dysregulation, oxidative stress, mitochondrial dysfunction. What makes the photobiomodulation research compelling for RA is that it appears to modulate several of these systems at once, through different mechanisms, without the immunosuppression that limits our pharmacological options. For my patients considering a home device, I give them the same short list every time: the right wavelengths, enough power to reach the joint, and a protocol they will use consistently. Those are the parameters that did the work in the trials.— Dr. William Carter, MD
Why the Cura ProWave Deep Healing Pad™ Uses LEDs Instead of Lasers
Most of the clinical evidence for light therapy in RA comes from professional lasers used in clinics and laboratories. The three meta-analyses pooled trials that predominantly used laser devices. So if the strongest evidence used lasers, why does the Cura ProWave Deep Healing Pad™ use LEDs?
The Biology Does Not Require a Laser
The cellular response to light depends on the wavelength and dose delivered to tissue, not on the type of device. A photon at 660 nm triggers the same response in cytochrome c oxidase — the mitochondrial enzyme that initiates the entire photobiomodulation cascade — whether it comes from a laser or an LED. Hamblin (2017) established that the biological effects of photobiomodulation depend on wavelength, dose, and intensity, not on the laser-versus-LED distinction. The most thorough peer-reviewed analysis of this question, by Heiskanen and Hamblin (2018) of Massachusetts General Hospital and Harvard, concluded that photobiomodulation does not appear to depend on lasers or coherence, and that LED therapy appears as effective as laser therapy for surface-tissue applications at matched wavelength and dose. De Oliveira et al. (2022) reviewed both low-level laser and LED across musculoskeletal conditions and concluded that light therapy offers a non-invasive, drug-free method for pain relief with no reported side effects.
For RA specifically, the key mechanistic studies used LED devices. The Ryu et al. (2023) study (the one that compared photobiomodulation directly to methotrexate and found the combination superior) used a 610 nm LED, not a laser. The Du et al. (2023) study that identified BMP4 as the first specific gene target for photobiomodulation in RA used a 630 nm LED. The preclinical evidence for the core inflammatory mechanisms in RA already comes from LED-based devices.
LED Covers the Entire Joint at Once
Rheumatoid arthritis does not affect a single point in a joint. The synovial membrane lines the entire joint capsule, and the inflammatory pannus tissue spreads across the joint surface. A clinical laser treats one small spot at a time and requires a trained practitioner to systematically move the probe across the joint. An LED array built into a flexible pad covers the entire joint area in one session, so no part of the synovium is missed and the full joint surface is treated simultaneously. The RA trials applied laser at multiple separate points per session; the Cura ProWave Deep Healing Pad™'s 360-LED array delivers that kind of multi-point coverage without manual repositioning.
LED Makes Daily Home Use Possible
The RA evidence consistently shows that results come from accumulated, consistent treatment. The Adly et al. (2022) trial ran sessions multiple times per week. The Cochrane review analyzed treatment courses of four to ten weeks. Clinical laser sessions mean a clinic visit each time, administered by trained staff, which is impractical to do daily over weeks and months, particularly for RA patients dealing with morning stiffness, fatigue, and limited mobility. A home LED device lets you treat every day at a time that works for your symptoms, without the barrier of scheduling clinic visits, which is the consistent, accumulated dosing the evidence rewards.
Safe for Unsupervised Use
The lasers used in the RA trials are Class 3B or higher medical devices that can damage the eyes on direct exposure and require trained operators and protective eyewear. LED devices run at power levels that do not carry those risks. The Cura ProWave Deep Healing Pad™ is an FDA Class 2 Medical Device and ISO Certified, with 0 V/m EMF output, so it can be used safely at home without the supervision a clinical laser requires.
How the Cura ProWave Deep Healing Pad™ Delivers Light Therapy for Rheumatoid Arthritis
Wavelengths
The Cura ProWave Deep Healing Pad™ is built around 120 medical-grade triple-chip LEDs: 240 light chips emitting near-infrared at 850 nm and 120 light chips emitting red at 660 nm, 360 total. Both fall within the wavelength ranges documented in the RA research. The 660 nm red light sits within the band where the strongest RA-specific LED evidence exists: close to the 610 nm used in the Ryu et al. (2023) study that suppressed NF-κB and NLRP3 inflammatory cascades and the 630 nm used in the Du et al. (2023) study that identified the first specific gene target for photobiomodulation in RA. The 850 nm near-infrared is close to the 810 nm used in the Harvard/Yamaura et al. (2009) study that reduced TNF-α and IL-1β in human RA synoviocytes and the 808 nm used in the Adly et al. (2022) randomized trial that achieved significant improvements in human RA patients. Near-infrared at 850 nm also penetrates deeper into the joint, reaching the synovial membrane and surrounding tissue that red light alone cannot access as effectively.
Power Density: Why It Matters for RA
The Cura ProWave Deep Healing Pad™ delivers 200 mW/cm², among the highest power density for a home-use LED device. Power density determines how much light energy reaches each area of tissue per second, and this matters because the RA research consistently shows that underpowered treatments fail. The Hsieh et al. (2014) dosimetry study found that low fluence (4.5 J/cm²) significantly reduced inflammatory cell infiltration, TNF-α, MMP3, and fibroblast-like synoviocytes in an RA model, while high fluence (72 J/cm²) showed no effect. The Stausholm et al. (2019) meta-analysis confirmed the same dose-dependent pattern in joint disease broadly: adequately dosed trials produced significant outcomes; underdosed ones did not. The one negative RA clinical trial (Meireles et al. (2010)) used 70 mW at 3 J/cm², parameters that fall below what the mechanistic studies show is effective.
Light loses intensity as it passes through skin, subcutaneous tissue, and the joint capsule. The energy reaching the synovial membrane is always less than the energy at the surface. Higher surface power density means more energy arrives at the target tissue where RA pathology occurs. At 200 mW/cm² across a 20-minute session, the Cura ProWave Deep Healing Pad™ delivers substantially more energy to joint tissue than lower-powered devices can, giving both the red and infrared wavelengths their best chance of reaching the therapeutic dose range at the synovium.
Full Joint Coverage
The pad measures 18 × 8 inches and is built from flexible neoprene that conforms to the shape of the joint. It can wrap around the knee, drape over the hands and wrists, cover the shoulder, or be positioned against any affected joint area. This matters because RA attacks the entire synovial lining, not a single point. The strap system was designed specifically for ease of use, particularly for RA patients who may have limited hand dexterity due to joint swelling and stiffness. Where clinical laser protocols required a practitioner to move a probe point by point across the joint, the Cura ProWave Deep Healing Pad™ treats the full area at once.
Three Treatment Modes
The device runs in three modes: red only (660 nm), infrared only (850 nm), and combined. Red light addresses surface inflammation in the skin and superficial tissue over swollen joints. Infrared reaches deeper into the joint capsule toward the synovial membrane, cartilage, and surrounding tissue where the core RA pathology occurs. Running each wavelength alone or together means treatment can be matched to the situation: combined mode for inflamed joints with both surface swelling and deeper synovial involvement, infrared mode when deeper tissue is the primary target, red mode for surface-level inflammation and skin-level effects. The Ryu et al. (2023) study demonstrated that different wavelengths suppress inflammation through different pathways (NF-κB suppression at 610 nm, cytokine reduction through a separate pathway at 810 nm (Yamaura et al., 2009)) so the ability to deliver both wavelengths simultaneously activates complementary biological responses.
Pre-Set Modes and Guided Routine
The Cura ProWave Deep Healing Pad™ includes pre-set modes with parameters chosen to land within the effective dose range documented in the RA research. This removes the guesswork that undermines generic light therapy devices, which is particularly important given the biphasic dose response: both too little and too much energy reduce the therapeutic effect (Hamblin, 2017). The pre-sets keep treatment within the therapeutic window. The device comes with a cellular restoration protocol and progress-tracking tools to help build a daily habit, because consistency is one of the single biggest determinants of outcome. The meta-analyses tied the strongest results to accumulated, regular treatment. A device used occasionally will not reproduce what the trials achieved.
CuraYou's Recommended Routine for Rheumatoid Arthritis
Based on the research parameters and how light travels through joint tissue, CuraYou recommends daily 20-minute sessions in the combined red-and-infrared mode for most RA patients. For joints with prominent surface swelling and heat, combined mode delivers both the surface-acting red and deeper-penetrating infrared wavelengths at once. For joints where deeper synovial inflammation is the dominant issue, the infrared-only mode concentrates energy where it is needed. Multiple joints can be treated in sequence during the same session or across separate sessions in the day. CuraYou's human support team can help tailor the routine — someone with active hand and wrist inflammation and someone with predominantly knee involvement may benefit from different positioning and mode settings.
Medical-Grade Quality and Real Support
The Cura ProWave Deep Healing Pad™ is an FDA Class 2 Medical Device and ISO Certified, with precise wavelengths within the ranges documented across the RA research base. Its 0 V/m EMF rating means no electromagnetic field exposure during treatment. The LEDs are rated for 50,000 hours, holding their output across years of daily use. It can be purchased with an HSA or FSA card and is backed by up to a 3-year warranty. CuraYou provides real human support to help tailor your routine and answer questions, not chatbot scripts, but people who understand the research and can help optimize your protocol. Hundreds of verified customer reviews document the results people report across a range of conditions.
Conclusion
The Cura ProWave Deep Healing Pad™ takes the research behind red and infrared light therapy for rheumatoid arthritis (three meta-analyses, randomized controlled trials, a head-to-head comparison with methotrexate, and a body of mechanistic evidence identifying nine distinct biological pathways) and builds it into a device made for daily home use. Its 660 nm red and 850 nm near-infrared LEDs sit within the wavelength ranges that produced significant results in RA-specific studies. Its 200 mW/cm² power density is built to deliver the kind of dosing the research shows is needed, and its 360-LED, 18 × 8 inch flexible pad treats the full joint area at once rather than one point at a time. The RA clinical trials measured significant improvements in inflammatory markers, oxidative stress, cellular energy production, and quality of life within four weeks, with the Cochrane review analyzing treatment durations of four to ten weeks. That timeline fits comfortably within CuraYou's 60-day risk-free return guarantee, which gives you time to follow the protocol, evaluate your response, or receive a full refund if it is not for you.
